Marker Therapeutics, Inc.

NasdaqCM:MRKR 주식 보고서

시가총액: US$27.7m

Marker Therapeutics 미래 성장

Future 기준 확인 2/6

Marker Therapeutics 의 수익은 연간 38.9% 감소할 것으로 예상되는 반면, 연간 수익은 70.7% 로 증가할 것으로 예상됩니다. 70.7% 연간. EPS는 연간 10.4% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-38.9%

수익 성장률

-10.4%

EPS 성장률

Biotechs 수익 성장28.3%
매출 성장률70.7%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트15 Nov 2024

최근 미래 성장 업데이트

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22
Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Marker Therapeutics EPS misses by $0.02

Nov 09

수익 및 매출 성장 예측

NasdaqCM:MRKR - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20262-67N/AN/A1
12/31/20254-44N/AN/A1
12/31/20245-11N/AN/A1
9/30/20245-10-9-9N/A
6/30/20244-10-11-11N/A
3/31/20243-12-14-14N/A
12/31/20233-14-16-16N/A
9/30/20233-14-20-20N/A
6/30/20234-17-27-27N/A
3/31/20234-14-18-21N/A
12/31/20224-20-27-27N/A
9/30/20224-26-26-26N/A
6/30/20223-33-27-25N/A
3/31/20222-43-36-31N/A
12/31/20211-42-30-27N/A
9/30/2021N/A-41-35-28N/A
6/30/2021N/A-36-34-27N/A
3/31/20210-31-35-24N/A
12/31/20200-29-29-20N/A
9/30/20201-25-24-19N/A
6/30/20201-23-23-19N/A
3/31/20200-23-19-19N/A
12/31/20190-21-19-18N/A
9/30/2019N/A-152-20-20N/A
6/30/2019N/A-151-18-18N/A
3/31/20190-150-16-16N/A
12/31/20180-148-15-14N/A
9/30/20180-15-11-11N/A
6/30/20180-15N/A-9N/A
3/31/20180-12N/A-9N/A
12/31/20170-11N/A-8N/A
9/30/20170-10N/A-8N/A
6/30/2017N/A-8N/A-8N/A
3/31/2017N/A0N/A-8N/A
12/31/2016N/A-2N/A-7N/A
9/30/2016N/A-3N/A-6N/A
6/30/2016N/A28N/A-5N/A
3/31/2016N/A-38N/A-4N/A
12/31/2015N/A-34N/A-4N/A
9/30/2015N/A-33N/A-4N/A
6/30/2015N/A-63N/A-3N/A
3/31/2015N/A-2N/A-3N/A
12/31/2014N/A-31N/A-2N/A
9/30/2014N/A-34N/A-1N/A
6/30/2014N/A-33N/A-1N/A
3/31/2014N/A-35N/A-1N/A

애널리스트 미래 성장 예측

수입 대 저축률: MRKR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MRKR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MRKR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MRKR 의 수익(연간 70.7% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: MRKR 의 수익(연간 70.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: MRKR 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견